Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.36 |
| ▸ | JAK2 | O60674 | 7/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.34 |
| ▸ | JAK1 | P23458 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | PRKACA | P17612 | 5/20 | 0.32 |
| ▸ | CDK2 | P24941 | 4/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.32 |
| ▸ | GSK3B | P49841 | 4/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | CSF1R | P07333 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | CDK7 | P50613 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859216 | 1.00 | GAA (0.43) | GAAPDPK1JAK2MAP2K1JAK1 | |
| SCHEMBL23208845 | 0.87 | — | — | |
| SCHEMBL29859433 | 0.86 | PDPK1 (0.36) | GAAPDPK1JAK2MAP2K1KDR | |
| SCHEMBL19989510 | 0.86 | PDPK1 (0.36) | GAAPDPK1JAK2MAP2K1KDR | |
| SCHEMBL19989468 | 0.84 | KDR (0.37) | GAAPDPK1JAK2MAP2K1KDR | |
| SCHEMBL29859747 | 0.84 | KDR (0.37) | GAAPDPK1JAK2MAP2K1KDR | |
| SCHEMBL29859572 | 0.82 | PDPK1 (0.34) | GAAPDPK1JAK2MAP2K1KDR | |
| SCHEMBL19989450 | 0.82 | PDPK1 (0.34) | GAAPDPK1JAK2MAP2K1KDR | |
| SCHEMBL29156258 | 0.75 | GAA (0.38) | GAAJAK2JAK1TYK2JAK3 | |
| SCHEMBL19989538 | 0.73 | LPL (0.33) | GAAKDRKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715608-B | Indazole compounds for use in tendon and/or ligament injuries | 诺华股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3515894-B1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3515894-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | Novartis AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2018-03-29 | — | — | US | disclosed |
| WO-2018055550-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | SLC10A2, MMP1, TNNI3 | GAA 4269/4885PDPK1 1841/4885JAK2 1270/4885 |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | MMP1, SLC10A2, TNNI3 | GAA 3844/4885PDPK1 1649/4885JAK2 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.